No Data
No Data
Guolian Securities: Increased attention to tumor immunology, recommend focusing on targeted drugs such as PD1/IL2 in pharmaceutical companies.
With the increasing attention to tumor immunity, and the successive launch of advantageous products, bullish on PD1/IL2 and PD1/IL15 targeted drugs.
Express News | Silo Pharma Shares Are Trading Higher After the Company Entered Into an Agreement With WuXi AppTec for a Preclinical Small Animal Study of SPU-16
Express News | Silo Pharma Inc - Enters Agreement With WuXi AppTec for Spu-16 Study
Hang Seng Index: Benefiting from policy support, biotechnology stocks have seen three consecutive months of inflows.
The Hang Seng Index company stated that there are signs of improvement in the recent situation of biotechnology stocks, as well as benefitting from policy support and three consecutive months of inflow of funds.
Breaking News: Contract research organizations are all on the rise, with Genscript Bio Technology leading the way with a 7.56% increase and WuXi AppTec with a 5.57% increase.
On August 6th, CXO concept stocks rose across the board. As of press time, Genscript Bio (01548.HK) rose 7.56% to HKD 12.8; Wuxi Apptec (02359.HK) rose 5.57% to HKD 35.05; Pharmaron (03759.HK) rose 3.64% to HKD 9.96; Wuxi Bio (02269.HK) rose 3.06% to HKD 11.44. The market source is from Futubull. On the news front, on August 6th, Daly of the Federal Reserve stated that the economy has been slowing down for the past few months; regarding the upcoming meeting in September.
The concept of contract research organizations is on the rise. Wuxi AppTec (02359) rose by 4.97%. Institutions predict that the performance of the pharmaceutical sector will show a marginal improvement trend.
Jingu Finance News | The concept of contract research organizations is up across the board. As of press time, Genscript Bio (01548) rose 6.07%, Wuxi AppTec (02359) rose 4.97%, Viva Biotech (01873) rose 4%, and Pharmaron (03759) rose 3.64%. On the news front, Xingye Securities issued a research report stating that the market attention to the pharmaceutical sector has gradually recovered recently. Looking back, the pharmaceutical sector experienced a downtrend of more than 2 months, with the CSI 300 Index down 11.0% (as of the close of August 2), while the Shanghai and Shenzhen 300 Index was also down 6.1% during the same period. Currently, the pharmaceutical sector is valued
No Data